HK1082411A1 - Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders - Google Patents

Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders

Info

Publication number
HK1082411A1
HK1082411A1 HK06102790.2A HK06102790A HK1082411A1 HK 1082411 A1 HK1082411 A1 HK 1082411A1 HK 06102790 A HK06102790 A HK 06102790A HK 1082411 A1 HK1082411 A1 HK 1082411A1
Authority
HK
Hong Kong
Prior art keywords
treatment
serotonin reuptake
reuptake inhibitors
mood disorders
carbostyril derivatives
Prior art date
Application number
HK06102790.2A
Other languages
English (en)
Inventor
Kikuchi Tetsuro
Iwamoto Taro
Hirose Tsuyoshi
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32716306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1082411(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of HK1082411A1 publication Critical patent/HK1082411A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
HK06102790.2A 2002-12-27 2006-03-03 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders HK1082411A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002379003 2002-12-27
US47048103P 2003-05-14 2003-05-14
PCT/JP2003/016724 WO2004060374A1 (en) 2002-12-27 2003-12-25 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders

Publications (1)

Publication Number Publication Date
HK1082411A1 true HK1082411A1 (en) 2006-06-09

Family

ID=32716306

Family Applications (3)

Application Number Title Priority Date Filing Date
HK06102790.2A HK1082411A1 (en) 2002-12-27 2006-03-03 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
HK07109436.6A HK1101550A1 (en) 2002-12-27 2007-08-30 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
HK10111807.8A HK1145291A1 (en) 2002-12-27 2010-12-16 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders 5-

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK07109436.6A HK1101550A1 (en) 2002-12-27 2007-08-30 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
HK10111807.8A HK1145291A1 (en) 2002-12-27 2010-12-16 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders 5-

Country Status (27)

Country Link
US (5) US9387182B2 (xx)
EP (2) EP1575590B1 (xx)
JP (1) JP4284524B2 (xx)
KR (2) KR100858852B1 (xx)
CN (2) CN1989968B (xx)
AT (1) ATE376419T1 (xx)
AU (1) AU2003295235B2 (xx)
BR (1) BR0317771A (xx)
CA (1) CA2511619C (xx)
CY (1) CY1108060T1 (xx)
DE (1) DE60317098T2 (xx)
DK (1) DK1575590T3 (xx)
EC (1) ECSP055885A (xx)
ES (1) ES2295677T3 (xx)
HK (3) HK1082411A1 (xx)
IL (1) IL169358A (xx)
MX (1) MXPA05006857A (xx)
MY (1) MY152919A (xx)
NO (1) NO333291B1 (xx)
NZ (2) NZ556779A (xx)
PE (1) PE20040923A1 (xx)
PL (1) PL211975B1 (xx)
PT (1) PT1575590E (xx)
RU (2) RU2356554C2 (xx)
SI (1) SI1575590T1 (xx)
WO (1) WO2004060374A1 (xx)
ZA (1) ZA200503873B (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102000336A (zh) 2003-05-23 2011-04-06 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
US20090198059A1 (en) * 2004-09-13 2009-08-06 Chava Satyanarayana Process for the preparation of polymorphs, solvates of aripiprazole using aripirazole acid salts
AU2005302589B2 (en) * 2004-10-28 2010-09-16 Sk Biopharmaceuticals Co., Ltd. Adjunctive therapy for depression
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
JO3227B1 (ar) 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
US20150174247A1 (en) 2012-06-29 2015-06-25 Maruishi Pharmaceutical Co., Ltd. Oral pharmaceutical preparation of aripiprazole
GB2542155B (en) 2015-09-09 2018-08-01 Gw Pharma Ltd Use of cannabidiol in the treatment of mental disorders
CN111455019A (zh) * 2018-05-03 2020-07-28 杭州端丽生物技术有限公司 化合物fty720在制备治疗行为和运动异常检测标记物中的应用
JP7211136B2 (ja) * 2019-02-14 2023-01-24 ニプロ株式会社 錠剤、および、その製造方法
EP3970710A4 (en) 2019-05-13 2023-06-14 VASTHERA Co. Ltd. PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DEGENERATIVE BRAIN DISEASES BY ACTIVATION OF AUTOPHAGY
CN114340606A (zh) 2019-05-15 2022-04-12 瓦西特拉有限公司 包含自噬激活剂作为活性成分的用于预防或治疗心脑血管疾病的组合物
US11080484B1 (en) * 2020-10-08 2021-08-03 Omniscient Neurotechnology Pty Limited Natural language processing of electronic records

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4310524A (en) 1980-04-11 1982-01-12 Richardson-Merrell, Inc. TCA Composition and method for rapid onset antidepressant therapy
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5114976A (en) 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5591884A (en) 1989-05-31 1997-01-07 Abbott Laboratories Dopamine agonists
US5500343A (en) 1990-02-07 1996-03-19 Board Of Regents, The University Of Texas System Allelic association of the human dopamine(D2) receptor gene in compulsive disorders
US5780051A (en) 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
US5663167A (en) 1992-12-09 1997-09-02 The United States Of America As Represented By The Department Of Health And Human Services Antipsychotic composition and method of treatment
IE930485A1 (en) 1993-06-28 1994-12-28 Hemisphere Ltd Antidepressant agents with a rapid onset of action
ZA948357B (en) 1994-06-16 1996-04-24 Lilly Co Eli Potentiation of drug response
WO1997023220A1 (en) 1995-12-22 1997-07-03 Eli Lilly And Company Method for treating depression
EP0906104A4 (en) 1996-03-25 2003-12-10 Lilly Co Eli PAIN TREATMENT PROCESS
CA2250187A1 (en) 1996-03-25 1997-10-02 Eli Lilly And Company Composition comprising olanzapine and a drug useful in the treatment of pain for use in the treatment of pain
US6159963A (en) 1996-03-29 2000-12-12 Eli Lilly And Company Method for treating substance abuse
IL121076A (en) 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
ZA977967B (en) 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
ZA982368B (en) 1997-03-27 1998-09-23 Akzo Nobel Nv New therapeutic combinations
EP0919234A3 (en) 1997-10-17 1999-08-25 Eli Lilly And Company Potentiation of pharmaceuticals by moxonidine
GB9801538D0 (en) 1998-01-23 1998-03-25 Merck Sharp & Dohme Pharmaceutical product
PT1073432E (pt) 1998-04-14 2007-10-22 Gen Hospital Corp Utilização da d-alanina ou da d-serina para o tratamento da esquizofrenia
GB2336534A (en) 1998-04-24 1999-10-27 Alec James Coppen Anti-depressant - Folic Acid Combination
US6500827B2 (en) 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
EA003469B1 (ru) 1998-05-08 2003-06-26 Фармация Энд Апджон Компани Новые лекарственные комбинации ингибиторов повторного поглощения норадреналина (иппна), предпочтительно ребоксетина и пиндолола
WO1999059593A1 (en) 1998-05-21 1999-11-25 Eli Lilly And Company Combination therapy for treatment of depression
US6960577B2 (en) 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
EP0958824A3 (en) 1998-05-22 1999-12-01 Eli Lilly And Company Olanzapine (zyprexa) in combination with fluoxetine (prozac), lithium or anticonvulsant for therapy of refractory depression
TR200003525T2 (tr) * 1998-05-29 2001-04-20 Eli Lilly And Company Bipolar bozuklukların tedavisi için kombinasyon terapisi
US20030027817A1 (en) 1998-05-29 2003-02-06 Tollefson Gary Dennis Combination therapy for treatment of bipolar disorders
US6420349B1 (en) 1998-08-24 2002-07-16 Bristol-Myers Squibb Company Isoxazolinone antibacterial agents
WO2000030650A1 (en) 1998-11-23 2000-06-02 Sepracor Inc. Desmethylolanzapine compositions and methods
EP1135136B1 (en) 1998-11-23 2003-11-05 Sepracor Inc. Pharmaceutical compositions containing olanzapine-n-oxide
CA2352611A1 (en) 1998-11-23 2000-06-02 Sepracor Inc. 2-hydroxymethylolanzapine compositions and methods
EP1165090A2 (en) 1999-03-18 2002-01-02 Children's Hospital Research Foundation A method of treating bulimia nervosa and related eating disorders by administration of atypical antipsychotic medications
CA2363942A1 (en) 1999-04-06 2000-10-12 Sepracor Inc. Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites
US6281207B1 (en) 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
US6572890B2 (en) 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
US6599532B2 (en) 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US6322503B1 (en) 2000-02-17 2001-11-27 G. Roger Sparhawk, Jr. Method of diagnosing, tracking, and treating depression
DE10018834A1 (de) 2000-04-15 2001-10-25 Lohmann Therapie Syst Lts Transdermale oder transmucosale Darreichungsformen mit einer nicotinhaltigen Wirkstoffkombination zur Raucherentwöhnung
AU2002232470B2 (en) 2001-01-02 2005-11-03 Pharmacia & Upjohn Company Llc New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) * 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US20020123490A1 (en) 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
WO2002072145A1 (fr) 2001-03-14 2002-09-19 Ono Pharmaceutical Co., Ltd. Remedes antidepresseurs contenant un antagoniste ep1 en tant que principe actif
NZ528151A (en) 2001-04-19 2005-04-29 Warner Lambert Co Fused bicyclic or tricyclic amino acids
WO2002087590A1 (en) 2001-04-26 2002-11-07 Ortho-Mcneil Pharmaceutical, Inc. Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
DE10129320A1 (de) 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US6582737B2 (en) 2001-09-25 2003-06-24 Peirce Management, Llc Pharmaceutical composition containing two active ingredients for smoking cessation
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
WO2003066039A1 (en) 2002-02-08 2003-08-14 Abbott Laboratories Combination therapy for treatment of schizophrenia
EP1336406A1 (en) 2002-02-14 2003-08-20 Solvay Pharmaceuticals B.V. Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
WO2003101492A2 (en) 2002-05-30 2003-12-11 Neurosearch A/S Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain
WO2004011031A1 (en) 2002-07-29 2004-02-05 Potomac, Pharma, Llc. Antipsychotic combination therapies and compositions of an alpha-2 adrenergic receptor antagonist and an atypical antipsychotic neuroleptic
MXPA05000294A (es) 2002-07-30 2005-08-19 Peter Migaly Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
WO2004039361A1 (en) 2002-10-25 2004-05-13 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040121010A1 (en) 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
CN102000336A (zh) 2003-05-23 2011-04-06 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
MXPA06002778A (es) 2003-09-09 2006-06-14 Pfizer Prod Inc Combinacion de inhibidores de recaptacion de serotonina e inhibidores de recaptacion de norepinefrina.
WO2005051488A1 (en) 2003-11-26 2005-06-09 Pfizer Products Inc. Combination of dopamine agonists and monoamine reuptake inhibitors
EP1713486A4 (en) 2003-12-02 2009-04-29 Sheldon Leslie James COMBINED THERAPY FOR THE TREATMENT OF DEMENTIA, DEPRESSION AND APATHY

Also Published As

Publication number Publication date
AU2003295235A1 (en) 2004-07-29
CN1726039B (zh) 2010-08-18
IL169358A0 (en) 2007-07-04
KR100858852B1 (ko) 2008-09-17
AU2003295235B2 (en) 2008-06-19
JP2004217650A (ja) 2004-08-05
CA2511619A1 (en) 2004-07-22
RU2356554C2 (ru) 2009-05-27
US9387182B2 (en) 2016-07-12
IL169358A (en) 2013-04-30
PE20040923A1 (es) 2005-01-22
CN1989968A (zh) 2007-07-04
DK1575590T3 (da) 2008-02-11
MXPA05006857A (es) 2005-08-18
EP1575590B1 (en) 2007-10-24
PL211975B1 (pl) 2012-07-31
CA2511619C (en) 2011-07-12
HK1145291A1 (en) 2011-04-15
RU2389490C2 (ru) 2010-05-20
PT1575590E (pt) 2007-12-06
EP1723957A2 (en) 2006-11-22
ATE376419T1 (de) 2007-11-15
EP1575590A1 (en) 2005-09-21
KR20070093001A (ko) 2007-09-14
CN1989968B (zh) 2011-05-11
EP1723957A3 (en) 2013-01-23
US20160310489A1 (en) 2016-10-27
US20140221388A1 (en) 2014-08-07
KR100842694B1 (ko) 2008-07-01
JP4284524B2 (ja) 2009-06-24
US20200289501A1 (en) 2020-09-17
RU2005123808A (ru) 2006-02-20
DE60317098T2 (de) 2008-08-07
NO333291B1 (no) 2013-04-29
HK1101550A1 (en) 2007-10-18
CN1726039A (zh) 2006-01-25
US20170258788A1 (en) 2017-09-14
PL378214A1 (pl) 2006-03-20
ECSP055885A (es) 2005-11-22
ES2295677T3 (es) 2008-04-16
NO20052359D0 (no) 2005-05-12
BR0317771A (pt) 2005-11-22
CY1108060T1 (el) 2014-02-12
SI1575590T1 (sl) 2008-04-30
US20190151308A1 (en) 2019-05-23
NZ540054A (en) 2007-09-28
US9694009B2 (en) 2017-07-04
WO2004060374A1 (en) 2004-07-22
MY152919A (en) 2014-12-15
ZA200503873B (en) 2006-08-30
DE60317098D1 (de) 2007-12-06
KR20050085906A (ko) 2005-08-29
NZ556779A (en) 2008-12-24
RU2008131331A (ru) 2010-02-10
NO20052359L (no) 2005-07-18

Similar Documents

Publication Publication Date Title
HK1145291A1 (en) Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders 5-
IL230025A0 (en) Carbosteril history and mood stabilizers for the treatment of mood disorder
NO20060392L (no) Kombinasjon av SRC kinase inhibitorer kemoterapeutiske midler for behandling av proliferative sykdommer
DE60330187D1 (de) Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
EE200300440A (et) Epotilooni analoogide ja kemoterapeutikumide kombinatsioon proliferatiivsete haiguste raviks
ATE508114T1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
BR0316170A (pt) Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer
MXPA05005314A (es) Compuestos de lapacona novedosos y metodos de uso de los mismos.
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
TWI315669B (en) Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
ATE328608T1 (de) Verfahren und zusammensetzungen mit kombinationen aus terfenadinmetaboliten und leukotrienhemmer
AU2003227521A1 (en) Combination of atypical antipsychotic and serotonin reuptake inhibitor for the treatment of chronic pain
MY141048A (en) Morpholine derivatives as norepinephrine reuptake inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20171225